EcoDrugPlus

Dopamine Receptor D1

Ensembl ID : ENSSDUG00000009570
Gene Symbol: DRD1
4 Cross references
188 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSSDUG00000020981
Gene Symbol: DRD1
3 Cross references
198 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSSDUG00000021084
Gene Symbol: DRD2
3 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSSDUG00000015458
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSSDUG00000005343
Gene Symbol: LOC111232170
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSSDUG00000015722
Gene Symbol: LOC111229041
3 Cross references
200 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSSDUG00000012801
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSSDUG00000005372
Gene Symbol: LOC111238889
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSDUG00000003346
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSSDUG00000010655
Gene Symbol: EGLN3
3 Cross references
198 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSSDUG00000013696
Gene Symbol: LOC111223860
3 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSSDUG00000018097
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).